DEF: HeartBeam, Inc. Announces 2025 Annual Shareholder Meeting Agenda, Proposing Director Elections and Significant Equity Plan Expansion

HeartBeam, Inc. has scheduled its 2025 Annual Meeting of Shareholders for July 11, 2025, where key proposals include the election of nine directors, the ratification of CBIZ CPAs as independent auditor, and a substantial amendment to increase authorized shares under the 2022 Equity Incentive Plan by 3,000,000 shares.

Summary

• HeartBeam, Inc. will hold its 2025 Annual Meeting of Shareholders virtually on Friday, July 11, 2025, at 1:00 p.m., Eastern Daylight Time.
• Shareholders will be asked to vote on the election of nine director nominees: Richard Ferrari, Branislav Vajdic, George A. de Urioste, Marga Ortigas-Wedekind, Willem Elfrink, Mark Strome, Kenneth Nelson, Michael Jaff, and Robert Eno.
• The agenda includes a proposal to approve the appointment of CBIZ CPAs P.C. as the independent registered public accounting firm for 2025.
• A significant proposal is to amend the 2022 Equity Incentive Plan to increase the authorized shares for issuance by 3,000,000, raising the total from 8,900,000 to 11,900,000 shares, plus up to 876,797 shares previously reserved under the 2015 Equity Plan.
• As of the record date, May 12, 2025, there were 33,809,707 shares of Common Stock issued and outstanding, with 3,256,785 shares available for grant under the 2022 Equity Plan.
• The proposed increase in authorized shares for the equity plan could result in an additional 9% dilution to existing shareholders.
• The company's executive compensation philosophy emphasizes equity awards over base salaries to align executive interests with shareholder interests.
• Robert Eno was appointed Chief Executive Officer in October 2024, succeeding founder Branislav Vajdic, PhD, who transitioned to President.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, indicating ongoing corporate governance and a focus on long-term talent retention through equity plans. The proposed increase in shares for the equity plan, while potentially dilutive, is framed as essential for attracting and retaining key personnel and aligning interests with shareholders, which is generally positive for long-term growth. The company is moving towards commercialization of its technology, which is a positive sign of progress.

Positives

• The company is seeking to expand its equity incentive plan, which is stated to be critical for attracting, retaining, and motivating qualified service providers and aligning their interests with shareholders for long-term success.
• The Board believes its current leadership structure, with separate CEO and Chairman roles, effectively serves oversight and leverages the experience of both positions.
• The establishment of a Commercialization Committee indicates a strategic focus on bringing products to market, advising on product strategy, target markets, and go-to-market efforts.
• The Compensation Committee has determined that the company's compensation policies and practices do not create risks reasonably likely to have a material adverse effect on the company.

Negatives

• The proposed increase of 3,000,000 shares for the 2022 Equity Incentive Plan could lead to an additional 9% dilution for existing shareholders.
• One director, Mr. George de Urioste, submitted one late Form 4 filing in 2024 regarding initial securities disclosures.

Risks

• Potential dilution to existing shareholders due to the proposed increase in authorized shares for the 2022 Equity Incentive Plan.
• Tax implications related to executive compensation under Section 162(m) of the Code, which limits deductibility of compensation over $1,000,000, and Section 409A, which imposes additional taxes and penalties for non-compliant deferred compensation.

Future Outlook

The company aims to continue attracting, retaining, and motivating qualified service providers through equity compensation, aligning their interests with shareholders and fostering an ownership mentality for long-term health and profitability. The Compensation Committee will conduct a full review of equity ownership in 2025 to establish long-term incentives for the CEO role that align with peer group benchmarks and are in line with increasing shareholder value. A key milestone for executive option vesting is FDA clearance for marketing of HeartBeam's synthesized 12L product.

Management Comments

• "It is our pleasure to invite you to attend HeartBeam, Inc.s 2025 Annual Meeting of Shareholders." Robert Eno, Director and Chief Executive Officer.
• "Our management will report on our progress and respond to your questions."
• "The Board believes that its current leadership structure best serves the objectives of the Boards oversight of management; the ability of the Board to carry out its roles and responsibilities on behalf of the Shareholders; and the Companys overall corporate governance."
• "The Board also believes that the current separation of the Chairman and CEO roles allows the CEO to focus his time and energy on operating and managing the Company and leverages the experience and perspectives of the Chairman."
• "The Board believes the proposed Amendment is necessary to the long-term health of our company in order to support the effectiveness of our compensation, including executive and director compensation programs."
• "We provide long-term incentives to our executives, employees, advisors and directors in the form of equity compensation, which we believe aligns their interests with the interests of our shareholders and fosters an ownership mentality that drives optimal decision-making for the long-term health and profitability of our company."
• "Equally important, equity compensation is critical to our continuing ability to attract, retain and motivate qualified service providers."
• "The Board believes that the approval of the Amendment is essential to HeartBeams continued success, and in particular, HeartBeams ability to attract and retain outstanding and highly skilled individuals in the extremely competitive labor marks in which HeartBeam will compete. Such awards are also crucial to HeartBeams ability to motivate employees to achieve its goals."

Industry Context

The document highlights HeartBeam's position in the medical technology and digital health sectors, specifically focusing on cardiovascular devices and its groundbreaking 3D ECG technology. The company's emphasis on attracting and retaining talent in a "highly competitive labor market" underscores the intense competition for skilled professionals within this innovative industry. The mention of FDA clearance as a vesting milestone for executive options indicates the company is actively progressing towards the commercialization phase of its core technology, a critical stage for medtech startups.

Comparison to Industry Standards

• The Compensation Committee considers "competitive levels of compensation for executive positions based on information drawn from informal internal benchmark analysis of base salaries for executive officers at similarly sized, public medical technology companies."
• The long-term equity incentive program is designed to be "competitive as compared to other companies with who we compete for talent."
• For the CEO's long-term incentives, the Compensation Committee intends to "establish long-term incentives for the role that align to peer group benchmarks."
• No specific comparable companies, projects, or results are named beyond general references to "similarly sized, public medical technology companies" and "peer group benchmarks."

Management Changes

Corporate Governance

Related Party Transactions

• Since the beginning of fiscal year 2025, the Company did not have any transactions to which it has been a participant that involved amounts that exceeded or will exceed the lesser of (i) $120,000 or (ii) one percent of the average of the Company's total assets at year-end for the last two completed fiscal years, and in which any of the Company's directors, executive officers or any other related person as defined in Item 404(a) of Regulation S-K had or will have a direct or indirect material interest.

Stakeholder Impact

• Shareholders: Will vote on key proposals, including director elections and equity plan expansion (which could lead to dilution). Their interests are intended to be aligned with executive compensation.
• Employees/Executives/Directors: Will benefit from the expanded equity incentive plan, which is designed to attract, retain, and motivate them through long-term incentives. Their compensation structure is detailed.
• Auditors: CBIZ CPAs P.C. has been appointed as the independent registered public accounting firm for 2025.

Next Steps

• Hold the 2025 Annual Meeting of Shareholders virtually on July 11, 2025.
• Shareholders to vote on the election of directors, ratification of the independent registered public accounting firm, and approval of the amendment to the 2022 Equity Incentive Plan.
• Management will report on company progress and respond to shareholder questions at the Annual Meeting.
• The Compensation Committee will conduct a full review of CEO equity ownership in 2025 to establish long-term incentives aligned with peer group benchmarks.
• Seek FDA clearance for marketing of HeartBeam's synthesized 12L product, which is a milestone for executive option vesting.

Key Dates

Recommendation

Keywords

HeartBeam, BEAT, SEC filing, proxy statement, annual meeting, shareholder vote, director election, corporate governance, equity incentive plan, stock options, executive compensation, auditor appointment, medical device, digital health, cardiovascular devices, 3D ECG, dilution